[go: up one dir, main page]

BR9810444A - Treatment of diabetes with rosiglitazone and insulin - Google Patents

Treatment of diabetes with rosiglitazone and insulin

Info

Publication number
BR9810444A
BR9810444A BR9810444-6A BR9810444A BR9810444A BR 9810444 A BR9810444 A BR 9810444A BR 9810444 A BR9810444 A BR 9810444A BR 9810444 A BR9810444 A BR 9810444A
Authority
BR
Brazil
Prior art keywords
insulin
treatment
diabetes
rosiglitazone
mammal
Prior art date
Application number
BR9810444-6A
Other languages
Portuguese (pt)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9810444A publication Critical patent/BR9810444A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"TRATAMENTO DE DIABETE COM ROSIGLITAZONA E INSULINA" Descreve-se um método para o tratamento de diabete melito e condições associadas à diabete melito em um mamífero, método esse que compreende administrar uma quantidade eficaz, atóxica e farmaceuticamente aceitável do Composto (I) e insulina, a um mamífero que dela necessite."TREATMENT OF DIABETES WITH ROSIGLITAZONE AND INSULIN" A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal is described, a method which comprises administering an effective, non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin , to a mammal that needs it.

BR9810444-6A 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin BR9810444A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
BR9810444A true BR9810444A (en) 2000-09-05

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810444-6A BR9810444A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR012997A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265D0 (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
EA004534B1 (en) 1999-04-23 2004-06-24 Смитклайн Бичам Плс Novel pharmaceutical
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
KR100699614B1 (en) * 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 Substituted 4-alkoxyoxazole Derivatives as Peroxysome Prolifer Activated Receptor Agonists
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719140T3 (en) * 1993-09-15 2008-03-03 Daiichi Sankyo Co Ltd Use of thiazolidinediones to prevent or delay the onset of NIDDM
CZ32998A3 (en) * 1995-08-10 1998-10-14 Warner-Lambert Company Preparation of medicament for reducing amount of exogenous insulin
KR19990045756A (en) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 NIDDM treatment using RXR agonists

Also Published As

Publication number Publication date
AR012997A1 (en) 2000-11-22
AU8216398A (en) 1999-01-04
EP0999837A1 (en) 2000-05-17
JP2002504138A (en) 2002-02-05
UA70299C2 (en) 2004-10-15
CN1133431C (en) 2004-01-07
HUP0003260A3 (en) 2001-12-28
PE104499A1 (en) 2000-01-13
TR199903095T2 (en) 2000-08-21
BG104059A (en) 2000-10-31
HUP0003260A2 (en) 2001-05-28
CO4940454A1 (en) 2000-07-24
EA004800B1 (en) 2004-08-26
KR20010013843A (en) 2001-02-26
IN189723B (en) 2003-04-19
IL133143A0 (en) 2001-03-19
DZ2521A1 (en) 2003-02-08
TW587937B (en) 2004-05-21
WO1998057636A1 (en) 1998-12-23
UY25050A1 (en) 2000-09-29
SK179399A3 (en) 2000-11-07
CA2294141A1 (en) 1998-12-23
AP9901718A0 (en) 1999-12-31
ID23951A (en) 2000-06-08
PL343123A1 (en) 2001-07-30
AP1287A (en) 2004-06-26
MA26511A1 (en) 2004-12-20
AR015894A1 (en) 2001-05-30
NO996265L (en) 1999-12-17
OA11517A (en) 2004-02-04
GB9712866D0 (en) 1997-08-20
EA200000042A1 (en) 2000-08-28
NO996265D0 (en) 1999-12-17
ZA985237B (en) 2000-02-17
CN1260715A (en) 2000-07-19

Similar Documents

Publication Publication Date Title
BR9810172A (en) Treatment of diabetes with thiazolidinedione and metformin
BR9810444A (en) Treatment of diabetes with rosiglitazone and insulin
BR9810445A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and diguanide
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
BR9911656A (en) Pharmaceutical composition, processes for the prevention or treatment of diabetes in a mammal, for the prevention or treatment of diabetic complications in a mammal and for the prevention or treatment of impaired glucose tolerance in a mammal, use of an insulin sensitizer, and, process to reduce the side effects of an insulin sensitizer or / and an anoretic administered to a diabetic mammal
BR9106977A (en) METHOD TO SUPPRESS AUTOIMMUNE DESTRUCTION OF PANCREATIC BETA CELUIAS, PHARMACEUTICAL FORMULATION, PROPHYLAXIS METHOD, METHOD TO PREVENT THE SURGE OF TYPE 1 DIABETES AND METHOD FOR TREATING A MAMMAL
BR0215018A (en) Antidiabetic Formulation and Method
EA200000748A1 (en) METHOD OF INTRODUCTION OF MONOMERIAL INSULIN ANALOGUES
DE69625157D1 (en) TREATMENT OF TYPE II DEABETES MELLITUS WITH AMYLINAGONISTS
BR9913932A (en) Use of glp-1 analogs in the treatment of stroke
BR0009524A (en) Use of a compound, and, pharmaceutical or veterinary composition
BR9810186A (en) Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor
BR9810142A (en) Diabetes treatment with thiazolidinedione and sulfonylurea
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor
DE69630527D1 (en) PREVENTING DISEASE WITH A DIABETES CHARACTER
ATE356209T1 (en) THYROID-STIMULATING HORMONE MUTANTS
EA200000141A1 (en) METHOD OF TREATMENT OF DIABETAS BY THIAZOLIDINDIONE AND SULFONYL URIDE
HK1041201A1 (en) Compatibility of beta agonists and antidiabetic agents
ES2135353A1 (en) USE OF 17 beta -ESTRADIOL, ANALOGS AND DERIVATIVES THEREOF FOR THE TREATMENT OF DIABETES MELLITUS AND ITS MANIFESTATIONS
BR9815220A (en) Use of thiazolidinediones for the treatment of hyperglycemia
BR9815219A (en) Use of thiazolidinediones for the treatment of hyperglycemia
ECSP982535A (en) NEW TREATMENT METHOD (I)
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP982591A (en) NEW METHOD OF TREATMENT IV
ECSP982541A (en) NEW METHOD OF TREATMENT II

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.